Kuros Bioscience (CSBTF) Reports 82% Surge in Q1 Medical Device Sales

 

• Kuros Bioscience (CSBTF, Financial) reports an impressive 82% surge in Q1 medical device sales.
• First-quarter sales soared to $28.8 million, signaling robust market demand.
• Achieved an adjusted EBITDA of $3.3 million, reflecting an 11.6% margin.

Strong Sales Growth in Q1

Kuros Bioscience (CSBTF) has reported a remarkable 82% increase in medical device sales for the first quarter, reaching a substantial $28.8 million. This surge illustrates the company's solid footing in the medical device market, capturing significant growth potential.

Financial Performance Highlights

The company's group EBITDA stood at $2.0 million, indicating a healthy operational efficiency. Furthermore, Kuros Bioscience achieved an adjusted EBITDA of $3.3 million, which translates to a notable 11.6% margin. This financial achievement underscores the firm's adept management and strategic execution within the competitive medical industry.

Impressive Margins

The 11.6% margin in adjusted EBITDA highlights Kuros Bioscience's ability to maximize profitability while scaling operations. Such performance metrics are crucial for investors seeking stable and growth-oriented opportunities in the biotechnology sector.

https://www.gurufocus.com/news/2781250/kuros-bioscience-csbtf-reports-82-surge-in-q1-medical-device-sales

UnitedHealth (UNH) Positioned as Safe Haven Amid Tariff Concerns: Baird

 

• UnitedHealth (UNH, Financial) is prioritized by Baird for its stability and resilience in the healthcare sector.
• Analysts project a potential upside of over 9% based on current price estimates.
• GuruFocus estimates a substantial 21.49% upside, reflecting the stock's potential growth.

UnitedHealth: A Stable Choice in Volatile Markets

In the ever-changing landscape of health care, Baird has identified UnitedHealth (UNH) as a strong hold for stability. Renowned for its resilience against tariff impacts, UnitedHealth's focus on Medicare-related drug plans offers a strategic advantage. With an Outperform rating and a price target set at $640, Baird underscores UNH's robust domestic earnings stream as a cornerstone of its investment thesis.

https://www.gurufocus.com/news/2781259/unitedhealth-unh-positioned-as-safe-haven-amid-tariff-concerns

Novel Abbvie Agent Shows Promise in Early Parkinson’s Disease

 Tavapadon, a novel and highly selective partial agonist of dopamine D1 and D5 receptors, significantly improved motor function without increasing impulse control disorders in patients with early Parkinson’s disease (PD), results of two separate phase 3 studies showed.

The findings reflect outcomes from both fixed daily doses of 5 mg or 15 mg and flexible dosing regimens. An earlier phase 3 trial (TEMPO-3) also showed tavapadon to be a promising adjunct to levodopa in patients with PD experiencing motor fluctuations. 

“We have now shown D1/D5 agonists provide efficacy both in early and advanced disease, and the side effect profile was very similar across the three studies. This drug seems to be better than the current D2, D3 agonists,” study investigator Rajesh Pahwa, MD, professor of neurology and director of the Parkinson's Disease and Movement Disorder Center, University of Kansas, told Medscape Medical News.

The findings were presented April 7 at the American Academy of Neurology 2025 annual meeting.

Multiple Advantages 

None of the currently approved PD therapies, including dopaminergic agents such as levodopa and dopamine agonists (DAs) provided sustained relief from motor symptoms without a significant risk of adverse events (AEs).

DAs, particularly levodopa, may initially offer strong motor control, but efficacy often diminishes as the disease progresses, with some patients experiencing unpredictable motor fluctuations. AEs associated with both levodopa and DAs include excessive daytime sleepiness and impulse control disorders — potentially linked to the strong, repeated stimulation of D2/D3 dopamine receptors.

Tavapadon offers several advantages over existing PD treatments. By targeting D1/D5 receptors, it selectively activates direct pathway medium spiny neurons, which may provide more robust relief of motor symptoms compared to D2/D3-selective DAs.

Its long half-life supports once-daily oral dosing, potentially enabling more consistent motor control than current therapies. Additionally, partial agonism at D1/D5 receptors may help minimize receptor desensitization, increasing the likelihood of sustained therapeutic benefit.

Results of one of the new studies, TEMPO-1, included 529 treatment-naive PD patients diagnosed within the previous 3 years who had a Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II score of 2 or more and an MDS-UDRS Part III score of 10 or more.

The MDS-UPDRS Part II includes self-evaluation of activities of daily life — including swallowing, dressing, hygiene, walking, and cutting food — while Part III includes clinician-scored motor evaluations.

Immediate Improvement

Participants had a mean age of 63.7 years, with a greater proportion of men (64.7%) than women. The average MDS-UPDRS score was 7.4 for Part II, 24.4 for Part III, and 31.8 for the combined total of Parts II and III.

Patients were randomly assigned to receive placebo or tavapadon at 5 mg or 15 mg per day. The primary endpoint was change in the combined score on the MDS-UPDRS Part II and Part III at 26 weeks versus placebo.

Those receiving the active drug showed a significant reduction in the primary outcome compared to placebo. The least squares mean (LSM) difference vs placebo was -11.5 (95% CI, -13.8 to -9.2; P < .0001) for the 5 mg dose and -12.1 (95% CI, -14.4 to -9.8; P < .0001) for the 15 mg dose.

“The improvements pretty much started right away and were maintained throughout the study, with the placebo group showing a slight improvement earlier and then worsening overall,” said Pahwa. Efficacy of the 5 mg and 15 mg doses “looked very, very similar,” he added. 

The study also showed that tavapadon significantly reduced MDS-UPDRS Part II scores at week 26 compared to placebo, with an LSM difference of -2.5 (95% CI, -3.3 to -1.7) for the 5 mg dose and -2.6 (95% CI, -3.4 to -1.7) for the 15 mg dose (both P < .0001).

Changes in Epworth Sleepiness Scale scores were similar across groups: -0.2 for placebo, -0.3 for 5 mg tavapadon, and -0.5 for 15 mg tavapadon.

Similarly, changes in total scores on the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) were comparable across all arms. The QUIP-RS assesses symptom severity and supports the diagnosis of impulse control and related disorders in PD.

The 5 mg dose was associated with fewer side effects than the 15 mg dose. For example, rates of nausea were 24% vs 27%, headache occurred in 12% vs 21%, and fatigue in 6% vs 8%, respectively.

The bottom line is that the 5 mg dose has about the same efficacy as the 15 mg dose and has somewhat of a safer side effect profile, said Pahwa. “Why would I use three times the dose with the risk of higher side effects when the efficacy is so similar,” he said. 

Tavapadon appears to meet the need for a more effective dopamine agonist with fewer side effects than currently available options, said Pahwa. However, he noted that the drug has not yet been directly compared with existing D2 and D3 agonists in head-to-head studies.

Similar Findings for TEMPO-2

The second study, TEMPO-2, closely mirrored TEMPO-1 but evaluated flexible dosing of tavapadon. It enrolled 304 treatment-naive patients with early PD who were randomized to receive either placebo or flexible-dose tavapadon (5-15 mg per day).

As in TEMPO-1, participants receiving tavapadon experienced a significant improvement in the primary outcome — change in the combined MDS-UPDRS Part II and III scores at week 26 — compared to placebo (LSM difference, -9.1; 95% CI, -11.7 to -6.5; P < .0001).

Tavapadon also significantly improved MDS-UPDRS Part II scores compared to placebo (LSM difference, -1.5; 95% CI, -2.4 to -0.6; P = .0007).

As in TEMPO-1, separation from placebo emerged within 4-8 weeks of treatment initiation. The side effect profile was also similar, with most treatment-emergent AEs in the tavapadon group were mild to moderate in severity. 

“We are very, very encouraged by these results,” Fernandez told delegates.

AbbVie is on track to submit a New Drug Application to the US Food and Drug Administration sometime this year.

Encouraging Research

Commenting for Medscape Medical News, Michael S. Okun, MD, Adelaide Lackner professor of neurology at the University of Florida and executive director of the Norman Fixel Institute for Neurological Diseases, said the findings are encouraging in the search for new treatments for PD.

“There’s great interest and need for drugs with selective D1/D5 dopamine receptor partial agonist activity as a path to minimize the common side effects of current dopamine agonist drugs, including impulse control disorders,” said Okun, who is also a medical advisor to the Parkinson’s Foundation.

“A drug that that can be given once a day and improve the amount of time Parkinson’s folks are in the ‘on’ state, with less impulse control, would be a welcome addition to our treatment armamentarium.’

Pahwa reports receiving compensation for consultancy and research funding from AbbVie. Fernandez reports serving as a consultant and advisory board member AbbVie. Okun has no relevant disclosures.

https://www.medscape.com/viewarticle/novel-agent-shows-promise-early-parkinsons-disease-2025a10008yx

RFK Jr. Says the Medical System Has 'Perverse Incentives' for Doctors

 HHS is trying to change the "perverse incentives" in the medical system, including the way doctors are paid, HHS Secretary Robert F. Kennedy Jr. said Tuesday.

"A lot of the negative behavior and self-destructive behavior in both the medical system -- how we pay for healthcare -- and how we eat is driven by perverse incentives," Kennedy said at a press conference at the Indiana State Library in Indianapolis. "Today, we have a healthcare system that reimburses doctors and hospitals for procedures rather than for health outcomes. We have to change that."

On another front, Kennedy also said that the CDC "has done a very good job at controlling the measles outbreak. We've had about 700 cases nationally and in Europe, they've had 127,000 cases and 37 deaths." That number contrasts with 2024, in which 285 measles cases were reported in the U.S. for the entire year, according to the CDC

opens in a new tab or window.

"People get measles because they don't vaccinate. They get measles because the vaccine wanes -- the vaccine wanes about 4.8% per year, so you know that problem is always going to be around," he continued. "We need to also make sure that doctors know how to treat measlesopens in a new tab or window and how to treat the associated diseases, the pulmonary disease that often comes with measles, and [the] bacteriological [ones] -- we can't rely simply on the vaccine."

In contrast to Kennedy's remark, experts say that the measles vaccine provides lifelong immunityopens in a new tab or window, which is how the U.S. achieved elimination status.

It's "outrageous" that the government doesn't have a better surveillance system for vaccine injuries, Kennedy said in response to a question from the audience -- which was not audible on the livestream -- that apparently raised the issue of a possible connection between vaccines and autism, a relationship that has been widely debunked

opens in a new tab or window.

The CDC did a study on HHS's surveillance system, the Vaccine Adverse Event Reporting System -- which allows for self-reporting of possible vaccine-associated injuries but does not verify them -- in 2010, "and [found that] it captures fewer than 1% of vaccine injuries," he said, noting that at the time, the CDC had a "machine counting" system for such injuries but they "put it on a shelf."

"We are going to improve the surveillance," Kennedy said. "We're going to get the data sets from everybody we can. We're going to make data-sharing agreements with scientists all over the world, with the best scientists, and we're going to find out what contribution vaccines and everything else make -- mold, EMF [electromagnetic fields], food, all of these other exposures -- which one of those are the culprits? I suspect we're going to see that there's a lot of culprits, but we need to know."

"People don't have informed consent [for vaccination], and people don't trust our agency anymore," he added. "And the way to improve vaccination is to make the agency trustworthy, and that's what we're going to do."

"Today, we have a healthcare system that reimburses doctors and hospitals for procedures rather than for health outcomes. We have to change that," said HHS Secretary Robert F. Kennedy Jr.

Kennedy also touched on the chronic illness he sees in the younger generation. "This whole generation of kids is damaged by chronic disease," he said. "I walk through an airport, and I see these young people -- you can see the chronic inflammation. You can see the mitochondrial challenges that they're facing." He noted that the U.S. is the fourth most obese country in the world, "and we have people who are obese and are at the same time malnourished because the food they're eating is not nutrient-dense."

Also at the press conference, Indiana governor Mike Braun (R) announced the signing of several executive orders

opens in a new tab or window on diet and health, including orders to:

• Ban the purchase of candy and soda with benefits from the Supplemental Nutrition Assistance Program (SNAP). One other state -- Arkansas -- has also asked the Agriculture Department for permission to ban those items.
• Change the work requirements for SNAP to make sure able-bodied recipients who aren't employed will get on a path to employment
• Make sure SNAP recipients who aren't eligible for the program are removed from the rolls
• Initiate a study of diet-related chronic illness
• Crack down on eligibility errors in Indiana's Medicaid program
• Pave the way for more direct-to-consumer sales of food from local Indiana farmers

CMS Administrator Mehmet Oz, MD, MBA, who also appeared at the press conference, applauded Braun's moves. Having nine executive orders to address issues favored by the "Make America Healthy Again" movement, which Kennedy supports, "I think that breaks the record," he said. "Moms know you win the battle for health in the home ... These executive orders make it easy for moms to do the right thing for their kids."

"My position as administrator of CMS is helping to ensure that the nation's health insurance programs create the right incentives, empower the right people, including especially patients, so they now feel like they own a piece of the rock, like they have agency over their future," Oz said.

He listed three ideas for improving the nation's health. "The first is walking," Oz said. "If every American walked for 20 minutes a day ... it would probably reduce our healthcare budget by about $100 billion."

Next was proper nutrition. "It turns out that the healthiest way to address food is to eat food that looks the way it looks coming out of the ground," he said. "That's why butter is better than hydrogenated oils, because it doesn't matter if butter might cause other issues -- it's real food. Your body knows what to do with it."

And last was increasing community involvement. "The number one driver of an expensive patient is a patient without another person in their life," he said. "Loneliness ends up driving a lot of the pathology that we then have to deal with in the healthcare system. The way you deal with that is by having community groups that work together well."

https://www.medpagetoday.com/publichealthpolicy/healthpolicy/115141

'Autism Rates Hit Record High, CDC Data Show'

 U.S. autism rates reached a record high, with about one in 31 children identified with autism spectrum disorder (ASD) in 2022, new CDC data suggested.

The prevalence of ASD among children 8 years old was higher in 2022 than previous years, reported Kelly Shaw, PhD, of the CDC's National Center on Birth Defects and Developmental Disabilities, in Morbidity and Mortality Weekly Reportopens in a new tab or window.

In 2020opens in a new tab or window, an estimated 2.8% of 8-year-old children were identified with ASD (27.6 per 1,000). Prevalence increased from one in 150 in 2000 to one in 36 in 2020, and demographic patterns in identifying ASD changed.

"Differences in prevalence over time and across sites can reflect differing practices in ASD evaluation and identification and availability and requirements that affect accessibility of services (e.g., meeting financial or diagnostic eligibility requirements)," Shaw and co-authors stated.

"As evidence grows of increased access to identification among previously underserved groups, attention might shift to what factors, such as social determinants of health, could lead to higher rates of disability among certain populations," they added.

The findings come from the CDC's Autism and Developmental Disabilities Monitoring (ADDM) network, which tracked autism prevalence in 16 communities nationwide. The ADDM network, which reports biennial ASD estimates in children, expanded from 11 to 16 communities when five additional sites joined in April 2023.

In 2022 -- the most recent information to date -- ASD prevalence was 32.2 per 1,000 8-year-old children across all 16 ADDM sites, ranging from 9.7 in Texas (Laredo) to 53.1 in California. ASD was 3.4 times as prevalent in boys (49.2 per 1,000) than in girls (14.3 per 1,000), the CDC said.

Prevalence was lower among white children (27.7 per 1,000) than among children who were Asian or Pacific Islander (38.2 per 1,000), American Indian or Alaska Native (37.5 per 1,000), non-Hispanic Black or African American (36.6 per 1,000), Hispanic or Latino (33.0 per 1,000), or multiracial (31.9 per 1,000).

The study also looked at ASD rates among 4-year-old children and found a higher rate by 48 months among children born in 2018 compared with children born in 2014.

The cohort of 4-year-olds born in 2018 received more evaluations and ASD identifications than the cohort born in 2014 did during the same age window, Shaw and colleagues pointed out. Disruption was visible in early 2020 at the onset of the COVID-19 pandemic, but a pattern of higher identification re-emerged by the end of 2020.

"Increased identification of autism, particularly among very young children and previously under-identified groups, underscores the increased demand and ongoing need for enhanced planning to provide equitable diagnostic, treatment, and support services for all children with ASD," the CDC researchers wrote.

While there's no single cause of autism, several factors may have fueledopens in a new tab or window rising prevalence numbers over the years, Alison Singer, president of the Autism Science Foundation, told MedPage Today earlier this year.

A redefinition of autism played a role, Singer said at the time. "The five subtypes of autism in DSM-IV, which included classic autism and Asperger's syndrome, collapsed into one overly broad category of autism spectrum disorder," she observed. Societal changes, including advanced maternal and paternal age, may have contributed in part.

Screening, surveillance, and awareness also have changed, said Susan Hyman, MD, of the University of Rochester Medical Center in New York, who co-authored the most recent American Academy of Pediatricsopens in a new tab or window (AAP) report on identifying and managing ASD.

The imperative to screen for ASD was recognized by parents and groups like the AAP when research showed that early intervention could improve functional skills in several developmental domains. "If improved functional outcomes were possible, identifying children who might benefit from them became an important movement," Hyman told MedPage Today in an interview earlier this year.

There's been "a catch-up in diagnoses" among medically underserved populations, Hyman pointed out. "While there continues to be inequity in services provided, gains have been made in recognizing the diagnosis," she said.

Last week, HHS Secretary Robert F. Kennedy Jr. said his agency will undertake a "massive testing and research effort" to determine the cause of autismopens in a new tab or window by September. Both Kennedy and President Donald Trump have suggested that vaccines could be to blame.

HHS also named David Geier -- a man without a medical degree who once was disciplined by the Maryland State Board of Physicians for practicing medicine without a license -- to lead a new studyopens in a new tab or window to identify whether a relationship between vaccines and autism exists.

Disclosures

Shaw reported no conflicts of interest.

Primary Source

Morbidity and Mortality Weekly Report

Source Reference: opens in a new tab or windowShaw KA, et al "Prevalence and early identification of autism spectrum disorder among children aged 4 and 8 years -- Autism and Developmental Disabilities Monitoring Network, 16 sites, United States, 2022" MMWR Surveill Summ 2025; DOI: 10.15585/mmwr.ss7402a1.

https://www.medpagetoday.com/neurology/autism/115143

Nvidia Plunges As US Imposes License On H20 Chip Sales To China, Imposes $5.5B Charge

 Nvidia tumbled in afterhours trading after the company said the US government will begin requiring a license to export the company’s H20 chips to China, an escalation of restrictions that the company has publicly opposed.

The government informed Nvidia on Monday that such a license would be in effect “for the indefinite future,” the company said in an 8K filing. The company now expects to report charges of about $5.5 billion during the fiscal first quarter from “inventory, purchase commitments and related reserves” tied to the H20 line, Nvidia said.

On April 9, 2025, the U.S. government, or USG, informed NVIDIA Corporation, or the Company, that the USG requires a license for export to China (including Hong Kong and Macau) and D:5 countries, or to companies headquartered or with an ultimate parent therein, of the Company’s H20 integrated circuits and any other circuits achieving the H20’s memory bandwidth, interconnect bandwidth, or combination thereof. The USG indicated that the license requirement addresses the risk that the covered products may be used in, or diverted to, a supercomputer in China. On April 14, 2025, the USG informed the Company that the license requirement will be in effect for the indefinite future. - 8K filing

As a reminder, the H20 is a scaled-down chip that was designed to comply with US export regulations and has been Nvidia's primary AI GPU legally available for sale in China after the H100/A100 were banned.

Bloomberg News reported in January that the Trump administration was exploring such a step. 

NVDA stock tumbled as much as 7% in afterhours trading as the market tried to make sense of this latest escalation in the trade war.

https://www.zerohedge.com/markets/nvidia-plunges-after-us-imposes-license-h20-chip-sales-china-slaps-company-55-billion

Congress Must Act To Stop 'Supreme Judicial Commanders' Of The Military

 by Elaine Donnelly via RealClearPolitics,

Former Majority Leader Senator Chuck Schumer recently admitted that he is responsible for confirming 235 “progressive” judges who are “ruling against Trump time after time.”  Activist judges are Schumer’s Plan B.

Article I, Section 8, of the U.S. Constitution empowers Congress to make policy for the military. But as things stand now, unelected, unaccountable federal judges are overruling President Trump’s Executive Orders and arrogating to themselves power to run the armed forces.

Unless the 119th Congress intervenes, President Joe Biden’s radical policies regarding transgender people in the military will continue indefinitely.

Self-Appointed “Supreme Judicial Commanders” Take Charge

President Donald Trump’s January 27 Executive Order #14183, titled “Prioritizing Military Excellence and Readiness,” is one of several calling for an undistracted focus on military warrior ethos, not “political agendas or other ideologies harmful to unit cohesion.” 

Executive #14168 (January 20) defined biological reality – differentiating “sex” from subjective “gender identity” and proclaiming the existence of two immutable sexes, male and female. This EO also prohibited male access to women’s sleeping, changing, or bathing facilities and discontinued use of inaccurate invented pronouns and bureaucratic markers that reflect subjective gender identity instead of biological sex.

The reality-based principles stated above, applied to DoD policies regarding persons having a history of gender dysphoria or identifying as transgender, logically justified orders to revoke President Joe Biden’s Executive Orders and Directives accommodating persons with gender dysphoria or identifying as transgender in the military.

Trump’s EOs and directives restored gender dysphoria to the DoD list of physical and psychological conditions that affect eligibility to serve, and ended Biden-era mandates and subsidies for irreversible treatments and surgeries for “transitioning” purposes that attempt to change sex.

Trump’s Executive Orders also mandated respectful treatment for persons separating with generous benefits due to gender dysphoria, and protected vulnerable children from chemical and surgical mutilation based on “junk science” recommended by discredited “experts” like the World Professional Association for Transgender Health (WPATH).

Lawsuits Filed to Halt Trump Gender Dysphoria/Transgender Policies

A lawsuit titled Nicolas Talbott v. U.S., plus two more, (Shilling v. Trump in Seattle and Ireland v. Hegseth in New Jersey), are challenging the directives and premises behind President Trump’s Executive Order regarding persons diagnosed with gender dysphoria or identifying as transgender.

In the Washington, DC Talbott case, District Judge Ana C. Reyes issued a nationwide preliminary injunction that blocked implementation of Trump’s order.  Judge Reyes, a longtime Democratic/left-wing activist described as the first gay Latina U.S. District Judge, displayed extreme bias in her handling of this case.  Her behavior toward the Justice Department attorney defending the Trump policy was so egregiously hostile, the office of the Attorney General filed a formal complaint. 

Not surprisingly, Judge Reyes’ March 18 opinion in the Talbott case lashed out at Trump’s recognition of only two sexes and concerns about male/female sexual privacy. Her strident rhetoric could be the start of a Plan B campaign of judicial lawfare against President Trump and his efforts to restore sound priorities in our military.

A similar national injunction in the Shilling case, a temporary restraining order in the Ireland case, plus additional adverse rulings expected from other activist judges, could make Biden’s extreme transgender policies permanent while various lawsuits wind their way to an unpredictable Supreme Court.     

Absent Congress Action, Biden Policies Likely to Become Permanent

The 78-page Talbott opinion exploited weaknesses in the government’s case, but Judge Reyes’ intemperate language and obvious bias showed why federal judges should not be making policy for our military.

Among other things, Judge Reyes disregarded Defense Department data on the costs and consequences of Obama-era treatments for gender dysphoria. In 2018, a DoD panel of experts reported to then-Defense Secretary James Mattis that 994 active-duty service members diagnosed with gender dysphoria accounted for 30,000 mental health visits – a 300% increase per capita. 

The Mattis panel’s report also cited long-term studies highlighting the operational and human costs of gender dysphoria, including disproportionately high risks of suicide. 

Why has this data not been updated? Perhaps because Biden’s policy prohibited discussion of problems with the transgender policy without approval from high-level officials.  Now Biden-era officials are praising their own policies before Congress and the courts.

We don’t know whether the Justice Department, representing the DoD, mentioned several empirical studies that have questioned lucrative treatments for gender dysphoria.  A 2025 University of Texas study, for example, reported elevated risks of depression and suicide following “gender-affirming surgery.” 

The Reyes ruling does not mention WPATH, a prominent organization advocating for irreversible puberty blockers and mutilating surgeries for minor children, which has been charged with medical ethics violations.  Nor does the record show consideration of the 2024 Cass Review in England, which questioned the benefits of “sex change” treatments for children.

Even if the Justice Department had presented many recent critical studies in court, the judge probably would have still described Trump’s policy (twice) as “soaked in animus and dripping with pretext.”

Judge Reyes’ over-the-top opinion showed zero concern about operational complications, medical ethics, and overwhelming public opinion against men entering women’s private facilities and athletic teams.  Activist court injunctions that usurp power from Congress and the Executive Branch are about reality-denying transgender ideology, not military effectiveness.

Congress Should Enact Common Sense in Defense Bill (NDAA) for 2026

Years could pass before the issue reaches the Supreme Court, which may or may not hand down a decision favoring the Trump policy. This puts the ball squarely in Congress’ court.

Without principled congressional action, accomplished in a way that can withstand judicial scrutiny, members could be held accountable for not delivering on promises made during the 2024 elections.

It would help to inscribe four essential principles in the National Defense Authorization Act (NDAA) for 2026: Merit as the exclusive basis for personnel actions, a prohibition on non-merit factors such as race in personnel actions, clear definitions of key terms such as “merit,’ “male,” and “female,” and narrow exceptions for operational reasons.

Congress also should dismantle ideological power bases in the Pentagon.  Non-discriminatory practices and common-sense, reality-based measures would support President Trump’s efforts to end woke policies in the military, while reaffirming purposes of the military that some federal judges refuse to respect.

Elaine Donnelly is President of the Center for Military Readiness (CMR), an independent public policy organization founded in 1993, which reports on and analyzes military/social issues. More information is available at www.cmrlink.org.

https://www.zerohedge.com/political/congress-must-act-stop-supreme-judicial-commanders-military